Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from Imunon ( (IMNN) ).
On July 11, 2025, Imunon, Inc. held its Annual Meeting of Stockholders where several key proposals were voted on. The stockholders elected Class III directors to serve until the 2028 annual meeting, ratified the appointment of WithumSmith + Brown, PC as the independent accounting firm for 2025, and approved the 2024 executive compensation plan. Additionally, they approved the issuance of shares under certain warrants, an increase in authorized shares from 112.5 million to 350 million, a potential reverse stock split, and an amendment to the 2018 Stock Incentive Plan.
The most recent analyst rating on (IMNN) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Imunon stock, see the IMNN Stock Forecast page.
Spark’s Take on IMNN Stock
According to Spark, TipRanks’ AI Analyst, IMNN is a Neutral.
Imunon’s financial instability, characterized by negative revenue and cash flow metrics, significantly impacts its overall stock score. Technical indicators suggest caution, with bearish trends and lack of momentum. Though the recent earnings call highlights promising clinical progress, concerns about cash runway and funding remain. Valuation metrics further reflect the stock’s risky profile, with a negative P/E ratio and no dividend yield.
To see Spark’s full report on IMNN stock, click here.
More about Imunon
Average Trading Volume: 11,767,890
Technical Sentiment Signal: Strong Sell
Current Market Cap: $14.43M
Find detailed analytics on IMNN stock on TipRanks’ Stock Analysis page.